Identification of a MAGE-2-encoded Human Leukocyte Antigen-A24-binding Synthetic Peptide That Induces Specific Antitumor Cytotoxic T Lymphocytes

Kouichirou Tahara, Kazutoh Takesako, Alessandro Sette, Esteban Celis, Seigo Kitano, and Tsuyoshi Akiyoshi

Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan [K. T., T. A.]; Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., Otsu, Shiga, Japan [K. T.]; Epimmune, Inc., San Diego, California [A. S.]; and Department of Immunology, Mayo Clinic, Rochester, Minnesota [E. C.]; and Department of Surgery I, Oita Medical University, Oita, 879-5593, Japan [K. T., S. K.]

ABSTRACT

Because MAGE-2 gene is expressed in a wide variety of malignant tumors and HLA-A24 is the most common allele in the Japanese population and is also frequently present in Caucasians, the identification of MAGE-2-encoded peptide presented by HLA-A24 is, therefore, considered to be important in order to develop specific immunotherapy for malignant tumors using peptides as a vaccine. By using a MHC-binding assay, eight peptides derived from MAGE-2 were found to bind with sufficient affinity to the HLA-A24 molecule. When the induction of specific cytotoxic T lymphocytes (CTLs) was examined using a simplified method, the highest human lymphocyte antigen (HLA) binder (EYLQLVFGI) in these peptides was able to elicit CTLs from unseparated peripheral blood mononuclear cells in HLA-A24 healthy donors by stimulation with freshly isolated, peptide-pulsed peripheral blood mononuclear cells as antigen-presenting cells and also by using interleukin 7 and keyhole-limpet hemocyanin in a primary culture. The induced CTL could, thus, lyse HLA-A24 tumor cells expressing MAGE-2, as well as the peptide-pulsed target cells, with antigen specificity in a HLA class I-restricted manner. The identification of this peptide may, thus, be of therapeutic value in peptide-based vaccines for the treatment of several types of malignant tumors expressing MAGE-2.

INTRODUCTION

The MAGE gene family comprises a series of at least 12 closely related genes (1). These genes are expressed in a number of malignant tumors of various histological origins but not in normal tissues with the exception of the testis (2). The antigenic peptides derived from MAGE-1 or -3 have been shown to elicit a CTL2 response in the context of HLA class I molecules (3–7). Therefore, immunization using these peptides has been investigated for specific immunotherapy in melanoma patients, and some clinical effectiveness has been reported (8–11). Regarding the MAGE-2 gene, two MAGE-2-derived synthetic peptides presented by HLA-A2 were shown to be capable of eliciting a CTL response in transgenic mice, although no recognition of HLA-A2 human tumor cell lines could be detected (12). However, one of these peptides has recently been demonstrated to be able to induce CTLs that kill human tumor cells expressing both HLA-A2 and MAGE-2 (13).

One way to identify potential peptides from tumor antigens is by means of an in vitro induction protocol of peptide-specific CTLs which consists of the stimulation of PBMCs by synthetic peptides with binding affinity to target HLA alleles (5). In line with this assumption, we developed a simplified method to efficiently induce MAGE-specific CTLs from PBMCs by in vitro stimulation with MAGE peptide, in which the CTLs were able to lyse human tumor cells expressing MAGE (14). Using this procedure, we have previously characterized MAGE-1 and -3-encoded peptides presented by HLA-A24 (15, 16).

The MAGE-2 gene was shown to be expressed in a relatively high proportion of melanomas as well as in several other types of malignant tumors (17). On the other hand, HLA-A24 is the most common allele in the Japanese population (18) and is also frequently present in Caucasians (19). Therefore, it is considered important to identify potential antigenic peptide derived from MAGE-2 presented by HLA-A24 for specific immunotherapy using the peptide as vaccine. In this study, we identified eight MAGE-2-derived peptides that bind with sufficient affinity to the HLA-A24 molecule, after defining the MHC-binding assay based on the screening of sequences for the presence of MHC-binding motifs. We then investigated the induction of MAGE-2-specific CTLs from the PBMCs of HLA-A24 healthy donors by in vitro stimulation with the synthetic peptides using our newly developed method.

MATERIALS AND METHODS

Cell Lines. The TISI cells, a human B-lymphoblastoid cell line showing HLA-A24, were provided by the Takara Shuzo Co., Ltd. (Otsu, Shiga, Japan). The esophageal carcinoma cell line KY150, the gastric carcinoma cell lines MKN-1 and

Received 3/18/99; accepted 5/21/99.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Department of Surgery I, Oita Medical University, Oita 879-5593, Japan. Phone: 81-97-586-5843; Fax: 81-97-549-6039.

2 The abbreviations used are: CTL, cytotoxic T lymphocyte; HLA, human lymphocyte antigen; PBMC, peripheral blood mononuclear cell; IL, interleukin; RT, reverse transcription; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
KATOIII, the colon carcinoma cell line WiDr, the breast carcinoma cell line MRKnu1, Raji, and K562 were supplied by the Japanese Cancer Research Bank (Tokyo, Japan). The esophageal carcinoma cell line TE11 was provided by the Tohoku University Cell Bank (Sendai, Japan). These cell lines were maintained in RPMI 1640 containing 10% fetal bovine serum and antibiotics.

MHC-binding Assay. The peptides derived from MAGE-2 sequence that were used for the MHC-binding assay were purchased from Chiron/Mimotopes (Clayton, Victoria, Australia). The peptides used as radioactive probes were synthesized in-house, purified by high-performance liquid chromatography, and radiiodinated. The peptide-binding assay specific for the class I molecule was described previously (20). In brief, the assay is based on the inhibition of the binding of radiolabeled standard peptides to detergent solubilized MHC molecules. The sequence of the standard peptide used for the MHC binding study for HLA-A24 was AYIDNYNKF. The standard peptide was radiolabeled using 125I by the chloramine-T method. HLA-A concentrations, yielding approximately 37°C. The cells were cultured in an RPMI 1640 supplemented with 5% heat-inactivated AB serum, 100 units/ml penicillin, 100 μg/ml streptomycin sulfate, and 50 μg/ml for 2 hr at 37°C. The PBMCs were prepulsed by purified peptides at a final concentration of 20 μg/ml for 2 hr at 37°C and then labeling them with keyhole limpet hemocyanin (5 mg/ml, Calkbiochem-Novobiochem, San Diego, CA) and IL-7 (25 ng/ml, Upstate Biotechnology, Lake Placid, NY). On day 4, recombiant IL-2 was then added to the culture at 30 IU/ml. The responder cells were stimulated every 7 days with freshly isolated autologous PBMCs that had been prepulsed with peptides and treated with mitomycin C (Kyowa Hakko, Osaka, Japan). The cultures were fed with a fresh medium containing IL-2 1 day after every stimulation. The CTL activity was assessed on day 42.

Phenotypic Analysis. Flow cytometry was performed using a FACScan. The cells were stained with murine antihuman monoclonal antibodies against CD3, CD4, and CD8 (Becton Dickinson, San Jose, CA). Isotype-matched murine antibodies (Becton Dickinson) served as negative control.

Cytotoxicity Assay. The target cells were labeled with 100 μCi of sodium 51chromate (51Cr) for 1 hr at 37°C, and the labeled cells were then washed and resuspended. The peptide-pulsed targets, TISI cells, were prepared by incubating the cells with the peptides overnight at 37°C and then labeling them with 51Cr. The effector cells were placed in each well of round-bottomed microtiter plates. The labeled target cells were then added to the well at a concentration of 3 × 10⁴ cells/well to produce a total volume of 0.2 ml. After a 4-h incubation period, the release of the 51Cr label was measured by collecting the supernatant, followed by quantitation in an automated gamma counter. Antigen specificity was determined by cold-target inhibition analysis by determining the capacity of peptide-pulsed, unlabeled TISI cells to block the lysis of carcinoma cells. The percentage of specific cytotoxicity was calculated as the percentage of specific 51Cr release: [(experimental release – spontaneous release)/(maximum release – spontaneous release)] × 100. To eliminate any specific lysis due to natural killer-like effectors, the cytolytic activity was tested in the presence of a 30-fold excess of unlabeled K562 cells. Some target cells were preincubuated for 48 h in the medium containing 300 units/ml IFN-γ (Pepro Tech, Rocky Hill, NJ) to enhance HLA expression.

Inhibition of the Cytotoxicity with Monoclonal Antibodies. Appropriate target cells were incubated with monoclonal antibodies at a final concentration of 1/20 for 1 hr at 4°C before the assay of cytotoxicity. The monoclonal antibodies used were anti-HLA class I antibody (Immunotech, Marseilles, France).

RT-PCR Analysis of MAGE-2 Expression. Total RNA was isolated from the tumor cell lines using the acid guani-51dimium thiocyanate-phenol-chloroform extraction procedure (21). cDNA was synthesized by RT from 2.5 μg of total RNA as described previously (22, 23). MAGE-2 cDNA was detected by PCR amplification using oligonucleotide primers specific for the different exons of the MAGE-2 gene. The primer sequences were 5'-AAGTAGGACCCCGACCTG-3' and 5'-GAA-GAGGAGAAGCGGTTCG-3'. PCR was performed for 33 cycles (30 sec at 94°C, 20 sec at 68°C, and 30 sec at 72°C). The PCR product was size-fractionated on 2% agarose gel. To ensure that the RNA had not degraded, a PCR assay with primers specific for the gene GAPDH cDNA was, thus, carried out in each case. The primers used for the amplification of GAPDH were 5'-GTCACCGATTGTTGTCGTATT-3' and 5'-AGTCCT-TCTGGGTGGCAGTGAT-3' (24).

RESULTS

Expression of MAGE-2 mRNA. The expression of MAGE-2 mRNA in all of the cell lines used in this study was analyzed using RT-PCR (Fig. 1). The MAGE-2 gene was expressed in KY150 (HLA-A24+), MKN-1 (HLA-A24+), WiDr (HLA-A24+), MRKnu1 (HLA-A24+), TE11 (HLA-A24+), and KATOIII (HLA-A24+). However, no expression of the MAGE-2 gene was detected in Raji (HLA-A24+) and TISI (HLA-A24+).

Identification of Peptides from MAGE-2 That Bind to HLA-A24. The known sequences of MAGE-2 were initially screened for peptides containing the anchor motif for HLA-A24. Eight peptides consisted of 9 or 10 residues were found to contain the binding motif for HLA-A24. These peptides were synthesized and tested for binding to purified HLA-A24 molecules. The results from the binding assay showed that three peptides bound to HLA-A24 with high affinity (<100 nM required to achieve 50% inhibition), and five peptides were intermediate HLA-A24 binders (100–1000 nM required for 50% inhibition; Table 1).
Induction of CTL Recognizing MAGE-2-encoded Synthetic Peptides. We stimulated the PBMC from at least three donors with the synthetic peptides using the simplified method for CTL induction. Of the eight peptides tested, the highest MHC binder (EYLQLVFGI) was able to elicit CTLs. After 42 days of culture, the induced effector cells lysed the TISI cells preincubated with different concentrations (0.04–20 μg/ml) of the peptide at various E:T ratios in a dose-related fashion, and, as shown in Fig. 2, the cells demonstrated approximately a 70% cytotoxicity against the TISI cells pulsed with 20 μg/ml of the peptide, compared with less than 10% cytolysis against the TISI cells alone at an E:T ratio of 60:1. No antipeptide or antitumor reactivities were apparently detected in the case of the remaining seven peptides.

Antigen Specificity of the Induced CTL. Antigen specificity of CTLs elicited with peptide EYLQLVFGI was further studied by testing its capacity to recognize various carcinoma cell lines and by determining the ability of peptide-pulsed, nonradiolabeled targets to inhibit the lysis of a MAGE-2+ and HLA-A24+ carcinoma cell line, MKN-1. The results presented in Fig. 3 show that the induced cells were capable of killing KY150, MKN-1 and WiDr cells, which were MAGE-2+ and HLA-A24+. However, the cytolysis was minimal against KATOIII (MAGE-2+, HLA-A24−) and Raji (MAGE-2+, HLA-A24−) cells. When the HLA-A24 carcinoma cell lines expressing MAGE-2 that showed even relatively low percentages of lysis by the CTLs were preincubated with IFN-γ, a significant level of lysis was observed (Fig. 4). Furthermore, the reactivity of the CTLs against carcinoma cells was apparently blocked by cold targets loaded with this peptide but not by cold targets pulsed with an irrelevant peptide (Fig. 5).

Characterization of the Induced Effectors. A flow cytometry analysis was performed before and after the culture in the case of the peptide EYLQLVFGI. The number of CD3+ cells gradually increased after the culture. The percentage of CD4+ cells decreased, whereas the CD8+ cells increased after day 14. On day 42, 99% of the cell population was CD3+, and approximately 80% of these cells were positive for CD8.

### Table 1

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Position</th>
<th>Binding (IC_{50}, nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EYLQLVFGI</td>
<td>156</td>
<td>3.4</td>
</tr>
<tr>
<td>VMPKTGLLII</td>
<td>195</td>
<td>52.2</td>
</tr>
<tr>
<td>SYVKVLHHTL</td>
<td>282</td>
<td>75.0</td>
</tr>
<tr>
<td>VMPKTGLLII</td>
<td>195</td>
<td>206.9</td>
</tr>
<tr>
<td>IFFSKASEYL</td>
<td>150</td>
<td>521.7</td>
</tr>
<tr>
<td>SFSTTINYTL</td>
<td>70</td>
<td>800.0</td>
</tr>
<tr>
<td>LYLVTCLGL</td>
<td>175</td>
<td>857.1</td>
</tr>
<tr>
<td>MFPDELESEF</td>
<td>97</td>
<td>857.1</td>
</tr>
</tbody>
</table>

* a Refer to the residue number of the first position of the peptide in relation to the sequence of the entire gene product.
* b Concentration of the peptide necessary to inhibit 50% binding of the radiolabeled test peptide to purified HLA-A24 molecules.

---

**Fig. 1** Expression of the MAGE-2 gene in cell lines detected by RT-PCR and agarose gel electrophoresis. PCR amplification was performed with specific oligonucleotides.

**Fig. 2** The cytotoxic activity of the induced cells by stimulation with MAGE-2/HLA-A24 peptide, EYLQLVFGI, against TISI cells pulsed with the peptide. The induced cells were obtained by stimulating PBMCs for 42 days with mitomycin C-treated autologous PBMCs pulsed with the peptide. TISI cells were pulsed, either with different concentrations (0.04–20 μg/ml) of or without peptide, overnight and then were labeled with ^51^Cr. The cytotoxic activity was assessed at various E:T ratios.

**Fig. 3** Lysis of various cell lines by the induced cells by using the peptide EYLQLVFGI. The cytotoxic activity of the induced cells was assessed against KY150 (esophageal carcinoma cell line, HLA-A24+, MAGE-2+), MKN-1 (gastric carcinoma cell line, HLA-A24+, MAGE-2+), WiDr (colorectal carcinoma cell line, HLA-A24+, MAGE-2+), KATOIII (gastric carcinoma cell line, HLA-A24+, MAGE-2+), and Raji (B-lymphoblastoid cell line, HLA-A24+, MAGE-2+) at various E:T ratios.
Inhibition of the Recognition of Effectors by Monoclonal Antibody. To determine whether the induced effector cells recognized the MAGE-2-expressing targets in a HLA-restricted manner, the monoclonal antibody generated against the HLA class-I molecules was used to block the recognition by effectors. The cytotoxic activity of effectors against the peptide-pulsed TISI cells was, thus, significantly eliminated by the anti-HLA class I antibody (Fig. 6). These results suggested that the induced effector cells lysed the targets in a HLA class-I-restricted manner.

DISCUSSION

The antigenic peptides derived from MAGE genes have been previously identified using several methods for the development of specific immunotherapy in cancer patients. The characterization of peptides encoded by MAGE-1 presented by HLA-A1 (3), HLA-A24 (16), and HLA-Cw1601 (25) have thus already been reported, and HLA-A1- (4, 5), HLA-A2- (6), HLA-A24- (15), and HLA-B44- (7) restricted peptides encoded by MAGE-3 have also been identified. With respect to MAGE-2, two MAGE-2-derived HLA-A2-binding peptides (KMVELVHFL and YLQLVFGIEV) that were capable of eliciting a CTL response in transgenic mice were shown to be processed and presented by HLA-A2, although the CTLs did not recognize human tumor cell lines (12). However, one of these peptides (YLQLVFGIEV) has recently been reported to elicit CTLs that could lyse tumor cells expressing both HLA-A2 and MAGE-2 by stimulation of PBMCs with the peptide (13). In the present study, we identified a MAGE-2-encoded peptide presented by HLA-A24 by means of the in vitro primary induction of peptide-specific CTLs, which were able to kill HLA-A24 human carcinoma cells expressing MAGE-2, from the PBMCs of healthy donors using HLA-A24-binding synthetic peptides.

For the identification of MAGE-encoded antigenic peptides, specific CTLs have been induced in vitro by the stimulation of the PBMCs from healthy donors with synthetic peptides by using rather complicated procedures (5–7). However, we have developed a simplified method for the induction of specific CTLs, in which the CTL responses could be induced from unseparated PBMCs by stimulation with freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells and by using IL-7 and keyhole limpet hemocyanine for a primary culture (14). Using this procedure, we identified a MAGE-2-encoded peptide presented by HLA-A24 by means of the in vitro primary induction of peptide-specific CTLs, which were able to kill HLA-A24 human carcinoma cells expressing MAGE-2, from the PBMCs of healthy donors using HLA-A24-binding synthetic peptides.
The HLA-A24-restricted MAGE-2 peptide identified here and the HLA-A2-restricted MAGE-2 peptides previously identified—both by using transgenic mice (12) and by stimulation of PBMCs with the peptide (13)—are derived from almost the same protein region. In fact, the peptide reported here (EYLQLVFGI) covers amino acids 156–164 and the amino acid sequence of the peptide presented by HLA-A2 (YLQLVFGIEV) is located at position 157–166. These results are reminiscent of the observation that a MAGE-3-encoded peptide presented by HLA-A1 is entirely included in the sequence of an HLA-B44-restricted MAGE-3 peptide (7).

Because of the tumor-specific expression of the MAGE genes, the antigens encoded by these genes may be potential targets for tumor-specific immunotherapy. Peptide-specific CTLs have been shown to be generated against MAGE-1- and -3-encoded peptides, and the antigenic peptides were demonstrated to be useful for the treatment of melanoma patients (8–11). Because peptide-specific CTLs were shown to be induced by a MAGE-2-encoded peptide presented by HLA-A24 in this study, immunization with this peptide may thus prove to be effective in vaccine therapy for patients with malignant tumors expressing MAGE-2.

Although two MAGE-2-derived peptides have been reported to be presented in the context of HLA-A2, the proportion of HLA-A2 individuals is 44% in Japanese and 49% in Caucasians (19). However, HLA-A24 is present in 61% of Japanese (18) but is only expressed in 10% of Caucasians (19). Therefore, the identification of a HLA-A24-restricted MAGE-2 peptide described in this study would result in an increased in number of patients with MAGE-2 positive malignant tumors, especially Japanese patients, who could thus benefit from immunization with the MAGE-2-encoded peptide.

The MAGE-2 gene is expressed in 70% of metastatic melanomas (26), in 41% of head and neck squamous cell carcinomas (27), in 37% of lung carcinomas (28), and in 30% of transitional carcinomas of the urinary bladder (29). Regarding gastrointestinal carcinomas, which are one of the most common malignant tumors in Japan, the MAGE gene expression was shown to be relatively high. MAGE-2 was thus expressed in 31% of gastric carcinomas (23) and in 43% of esophageal carcinomas (22). Therefore, immunization based on this MAGE-2-encoded peptide presented by HLA-A24 could be of therapeutic importance in patients with these carcinomas as well as in patients with melanoma.

Because we have recently identified the HLA-A24-restricted MAGE-3 and MAGE-1 peptides (15, 16), some HLA-A24 patients bearing malignant tumors expressing MAGE-1, -2, and -3 could be further immunized with a combination of these antigens, which may lead to a potentially more successful outcome. Moreover, immunotherapy with a synthetic peptide plus IL-2 in melanoma patients was reported to provide significantly higher tumor regression rates than those seen with either agent alone (30). Because the pretreatment of tumor cells with IFN-γ could enhance the cytolysis by CTLs as shown in this study, immunization with separate peptides derived from MAGE, including MAGE-2, in combination with cytokines, such as IL-2, may serve for the development of vaccine therapy in patients with various malignant tumors.

ACKNOWLEDGMENTS

We thank Dr. Masaki Mori for giving us appropriate advice. We also thank T. Shimoka, J. Miyake, K. Ogata, and K. Sato for their valuable technical assistance.

REFERENCES

22. Inoue, H., Mori, M., Li, J., Mimori, K., Honda, M., Nakashima, H., Mafune, K., Tanaka, Y., and Akiyoshi, T. Human esophageal carcino-
Identification of a MAGE-2-encoded Human Leukocyte Antigen-A24-binding Synthetic Peptide That Induces Specific Antitumor Cytotoxic T Lymphocytes

Kouichirou Tahara, Kazutoh Takesako, Alessandro Sette, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/5/8/2236

Cited articles
This article cites 29 articles, 7 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/5/8/2236.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/5/8/2236.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.